| Objective To observe the efficacy and safety of sertraline combined with low-dose olanzapine in the treatment of patients with comorbid depression and anxiety and its influence on sleep,and provide reference for clinicians. Methods 121 patients who met the diagnostic criteria of International Classification of Diseases,tenth edition(ICD-10) were selected from the Third people's Hospital of Tian shui and the Sanatorium for mental illness of Veterans in Tianshui from October 2019 to August 2020 were randomly divided into research group (n=61,took sertraline combined with low-dose olanzapine) and control group (n=60,did sertraline) for 8 weeks.Before and after treatment,Hamilton Depression Scale 17 (HAMD-17) and Hamilton Anxiety Scale (HAMA) were used to assess the severity of illness,Pittsburgh Sleep Quality Index (PSQI) was used to assess sleep quality,and TESS was used to assess adverse reactions at the end of the 1st,2nd,4th,6th and 8th week of treatment. Results At the baseline,there was no significant difference between the two groups in the scores of HAMD-17, HAMA and PSQI(all P＞0.05).After the treatment, the scores of HAMD-17, HAMA and PSQI were lower compared with the baseline(all P＜0.05).Comparing the same treatment period,the scores of HAMD-17, HAMA and PSQI in the research group were lower than those of the control group,there was significant difference two groups(all P＜0.05). Conclusion Sertraline combined with low-dose olanzapine and single sertraline are effective for patients with depression and anxiety,but sertraline combined with low-dose olanzapine is more effective and safe than single sertraline, Compared with the two groups, the research group is better than the control group in improving depression, anxiety and insomnia symptoms. |